Gylden Pharma https://validator.w3.org/feed/docs/rss2.html ChikungunyaTcP: characterization of the immunogenic response of a novel CD8 T cell priming vaccine against Chikungunya virus Using an integrated immunopeptidomic and HLA modeling system to develop a novel influenza A T-cell priming vaccine Rapid Emergex Antigen Deployment Initiative (READI): a synthetic T cell vaccine technology platform pairing a gold nanoparticle delivery system with select targets from a ligandome of prescreened pathogen derived, naturally processed & presented MHC-I peptides to provide rapid response solutions to combat and broadly protect against biothreat pathogens Characterization of a T cell adaptive vaccine platform to prime a broad and durable immunogenic response against Dengue virus infection Emergex T cell Chikungunya Vaccine: A Model for Emergex’s Synthetic T Cell Vaccine Platform as a Solution to Combat Alphaviruses Supporting Biothreat Preparedness Partners In the News Discovery of Novel Translated lncRNAs as Biomarkers in Colorectal Cancer Through Multi-omics Approaches Special Advisors Board of Directors News and Events Progressing Next-Generation Vaccines using Hollow Microneedle Delivery – Results from the naNO-Dengue and naNO-COVID Phase I Clinical Trial Emergex’s Next Generation Vaccines: Naturally processed & presented MHC class I ligandome libraries for the development of T cell priming immune set-point vaccines against infectious pathogens Conferences Data & Congress Presentations A novel immunoproteomic approach to MHC class I-restricted peptide discovery for influenza CD8+ T cell adaptive vaccine development Using targeted mass spectrometry to characterize the mechanism of action for a novel T cell-priming vaccine delivery system New approach: MHC class I peptide libraries for the treatment of viral and bacterial infectious diseases by innovative multi-epitope T cell adaptive vaccines Novel gene identification in the influenza virus infection model using multi-omics approach, reveals potential CD8+ T-cell adaptive vaccine candidates Label-free quantitative proteomics characterizes immunopathogenesis of Chikungunya virus infection in hepatocellular carcinoma cells Gylden’s 2025 Strategic Priorities for Advancing Innovative and Transformative Solutions for Infectious Diseases Novel immunopeptidomic discovery of MHC class I restricted SARS-CoV-2 peptides for next generation COVID19 T cell priming vaccines Characterization of the immunogenic response of a Chikungunya virus T cell adaptive vaccine Novel immunopeptidomic/machine learning integrated platform for next generation Chikungunya T cell priming vaccine development Quality Director Pipeline Technology About Us White Papers Advantages of Gylden’s Candidates Sergio Pagani Professor Thomas Rademacher Contact Us Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™ Careers Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic Applicator Emergex Receives Patent Protection for First-in-Class Influenza A Vaccines with Potential to Provide Long-Term T Cell Immunity Storme Moore-Thornicroft Bradley Norton Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have signed MoU to Advance First-of-its-Kind Infectious Disease Solutions Successful Transfer of New Drug Application (NDA), Acknowledged by U.S. FDA, from Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline Emergex Signs Contract of £1,79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate Emergex Appoints Sir Michael Rake as Board Chairman Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates Home